These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38464899)

  • 1. Taliglucerase alfa in the longterm treatment of children and adolescents with type 1 Gaucher disease: the Albanian experience.
    Cullufi P; Tomori S; Velmishi V; Gjikopulli A; Akshija I; Tako A; Dervishi E; Hoxha G; Tanka M; Troja E; Tabaku M
    Front Pediatr; 2024; 12():1352179. PubMed ID: 38464899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
    Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
    Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A; Wajnrajch M; Hernandez B; Pastores GM
    Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
    Titievsky L; Schuster T; Wang R; Younus M; Palladino A; Quazi K; Wajnrajch MP; Hernandez B; Becker PS; Weinreb NJ; Chambers C; Mansfield R; Taylor L; Tseng LJ; Kaplan P
    Orphanet J Rare Dis; 2022 Apr; 17(1):145. PubMed ID: 35365177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E
    Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
    Kuter DJ; Wajnrajch M; Hernandez B; Wang R; Chertkoff R; Zimran A
    Blood Cells Mol Dis; 2020 May; 82():102418. PubMed ID: 32146279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease.
    Hollak CE
    Core Evid; 2012; 7():15-20. PubMed ID: 22654679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa.
    Zimran A; Dinur T; Revel-Vilk S; Akkerman EM; van Dussen L; Hollak CEM; Maayan H; Altarescu G; Chertkoff R; Maas M
    J Inherit Metab Dis; 2018 Nov; 41(6):1259-1265. PubMed ID: 30066229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study.
    Revel-Vilk S; Mansfield R; Feder-Krengel N; Machtiger-Azoulay N; Kuter D; Szer J; Rosenbaum H; Ferreira DC; Ruhrman-Shahar N; Wajnrajch M; Zimran A
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa.
    Velmishi V; Troja E; Tanka M; Bali D; Dervishi E; Tako A; Kollcaku L; Cullufi P
    J Osteoporos; 2023; 2023():3254533. PubMed ID: 38090017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R; Park G; Damle B; Chertkoff R; Alon S
    PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
    Zimran A; Brill-Almon E; Chertkoff R; Petakov M; Blanco-Favela F; Muñoz ET; Solorio-Meza SE; Amato D; Duran G; Giona F; Heitner R; Rosenbaum H; Giraldo P; Mehta A; Park G; Phillips M; Elstein D; Altarescu G; Szleifer M; Hashmueli S; Aviezer D
    Blood; 2011 Nov; 118(22):5767-73. PubMed ID: 21900191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
    Gupta P; Pastores GM
    Pediatric Health Med Ther; 2017; 8():73-81. PubMed ID: 29388611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.